At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 163 enrolled
Drug / intervention
Losartan/Chlorthalidone in fixed dose +1 moredrug
Likely dose
Losartan/Chlorthalidone in fixed dose 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Confirmatory Study of the Efficacy and Safety of the Combination of Losartan / Chlorthalidone vs Losartan / Hydrochlorothiazide in the Treatment of Patients With Essential Arterial Hypertension
In Brief
A Phase 3 clinical trial evaluating Losartan/Chlorthalidone in fixed dose and Losartan + hydrochlorothiazide in fixed dose for Essential Arterial Hypertension. Completed, enrolled 163 participants across 1 site.
Detailed Summary
Phase IIIb, randomized, double-blind, prospective, multicenter study to evaluate the efficacy and safety of the fixed-dose combination of losartan / chlorthalidone compared with losartan / hydrochlorothiazide in the treatment of patients with essential arterial hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Arterial Hypertension
CountriesMexico
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartJun 2022
Primary CompletionAug 2023
Study CompletionSep 2023
TodayJul 2026
First PostedJun 15, 2021
Enrollment StartJun 30, 2022
Primary CompletionAug 15, 2023
Study CompletionSep 11, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.0 years ago
Interventions
Losartan/Chlorthalidone in fixed dosedrug
1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg
Losartan + hydrochlorothiazide in fixed dosedrug
1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg